In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Neogen’s current price exceeds the PERT-weighted fair value by 38.6%, indicating potential overvaluation supported by a negative DCF midpoint. Financial health shows strong liquidity and leverage but poor profitability and growth, raising risk concerns. Monte Carlo analysis indicates negligible downside risk below the current price, suggesting limited price contraction scenarios.